Oral Paclitaxel With P-Glycoprotein Pump Inhibitor Encequidar vs Intravenous Paclitaxel in Metastatic Breast Cancer

December 10-14, 2019; San Antonio, Texas
Oral paclitaxel significantly improved confirmed ORR with less neuropathy and more gastrointestinal toxicity vs IV paclitaxel in MBC.
Format: Microsoft PowerPoint (.ppt)
File Size: 207 KB
Released: December 20, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Daiichi Sankyo, Inc.
Genentech
Merck Sharp & Dohme Corp.
Puma Biotechnology
Seattle Genetics

Related Content

Experts provide their thoughts on key data in breast and gynecologic cancers from the 2022 ASCO Annual Meeting, from Clinical Care Options (CCO)

Joyce O'Shaughnessy, MD Angeles Alvarez Secord, MD, MHSc Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: August 17, 2022 Expired: August 16, 2023

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
Released: August 4, 2022

Commentary from Dr Heather McArthur on latest developments in managing early-stage breast cancer (EBC), from Clinical Care Options (CCO)

Heather McArthur, MD, MPH
Program Director
Released: August 4, 2022

Downloadable slideset from a live webinar presented by Sarah Hurvitz, MD, on selecting and sequencing targeted therapy for HR+/HER2- breast cancer, from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Released: July 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings